Lifecore Biomedical
LFCR
86 hedge funds and large institutions have $301M invested in Lifecore Biomedical in 2017 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 32 increasing their positions, 29 reducing their positions, and 8 closing their positions.
10% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 29
1.5% more ownership
Funds ownership: 90.54% → 92.04% (+1.5%)
8% less funds holding
Funds holding: 93 → 86 (-7)
12% less capital invested
Capital invested by funds: $340M → $301M (-$39.2M)
25% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 8
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$23.3M |
| 2 |
NIMC
NWQ Investment Management Company
Los Angeles,
California
|
+$8.7M |
| 3 |
Boston Partners
Boston,
Massachusetts
|
+$973K |
| 4 |
RA
Royce & Associates
New York
|
+$772K |
| 5 |
FP
Foundry Partners
Minneapolis,
Minnesota
|
+$708K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GC
Guggenheim Capital
Chicago,
Illinois
|
-$2.19M |
| 2 |
AI
Ariel Investments
Chicago,
Illinois
|
-$1.56M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$1.23M |
| 4 |
PPA
Parametric Portfolio Associates
Seattle,
Washington
|
-$778K |
| 5 |
CIP
Chartwell Investment Partners
Berywn,
Pennsylvania
|
-$566K |
LFCR Hedge Fund Activity: Q1 2017 in Review
86 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Lifecore Biomedical (LFCR) for Q1 2017, worth a combined $301M — down 12% from $340M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of LFCR and 6 opened new positions — a net loss of 2 holders — while 29 trimmed existing stakes and 32 added.
The largest buyer was BlackRock, adding an estimated $23.3M. The largest seller was Guggenheim Capital, exiting entirely with an estimated $2.19M sold.
- 86 institutional investors held Lifecore Biomedical (LFCR) as of Q1 2017, down from 93 in Q4 2016.
- Funds reported $301M of Lifecore Biomedical stock for Q1 2017, down 12% quarter-over-quarter.
- 6 funds opened new Lifecore Biomedical positions in Q1 2017 and 8 closed out, a net change of -2 holders.
- The largest Lifecore Biomedical buyer in Q1 2017 was BlackRock, an estimated $23.3M added.
- The largest Lifecore Biomedical seller in Q1 2017 was Guggenheim Capital, an estimated $2.19M sold.
Based on aggregated 13F filings for Q1 2017.